Worth reading
40Recurring
Scored from 2 of 5 sectionsDirection
Neutral
Direction inferred from the company’s description.Scale
13000000
¥Wording
Definitive
How definitive the wording is.Details of issuance or disposal
Issuance of the 7th Series of Stock Acquisition Rights (paid stock options)
Intended allottee
4 directors (excluding directors who are Audit and Supervisory Committee members, outside directors and seconded directors)
Total issue value
¥13,000,000
Terms of the stock acquisition rights
Exercise price
Initial exercise price of ¥438. The exercise price will be revised to the market price at the time of exercise (the closing price on the exercise request date), but will not be revised below ¥438 and will only be revised upward from ¥438. If a specified performance condition is achieved, namely, net sales exceeding ¥22.67 billion or operating profit exceeding ¥2.0 billion in any fiscal year from the fiscal year ending March 2028 through the fiscal year ending March 2030, the exercise price will be fixed at ¥438, with no subsequent market-price revisions.
Exercise period
1 August 2026 to 31 July 2035
Number of Stock Acquisition Rights
Total issued: 25,000. Unexercised balance: Not disclosed
Categories and Number of Persons Covered
4 directors (excluding directors who are Audit and Supervisory Committee members, outside directors and seconded directors), 25,000 stock acquisition rights
Payment date
7 August 2026 (date on which completion of payment of the full issue price was confirmed)
| Item | Details |
|---|---|
| Type of issuance or disposal | Issuance of the 7th Series of Stock Acquisition Rights (paid stock options) |
| Issue price and disposal price | ¥520 per stock acquisition right |
| Total issue value | ¥13,000,000 |
| Payment date | 7 August 2026 (date on which completion of payment of the full issue price was confirmed) |
| Intended allottee | 4 directors (excluding directors who are Audit and Supervisory Committee members, outside directors and seconded directors) |
| Exercise price | Initial exercise price of ¥438. The exercise price will be revised to the market price at the time of exercise (the closing price on the exercise request date), but will not be revised below ¥438 and will only be revised upward from ¥438. If a specified performance condition is achieved, namely, net sales exceeding ¥22.67 billion or operating profit exceeding ¥2.0 billion in any fiscal year from the fiscal year ending March 2028 through the fiscal year ending March 2030, the exercise price will be fixed at ¥438, with no subsequent market-price revisions. |
| Exercise period | 1 August 2026 to 31 July 2035 |
| Number of Stock Acquisition Rights | Total issued: 25,000. Unexercised balance: Not disclosed |
| Categories and Number of Persons Covered | 4 directors (excluding directors who are Audit and Supervisory Committee members, outside directors and seconded directors), 25,000 stock acquisition rights |
Items this document does not state (19)
Number of shares to be issued or disposed ofAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsIntended allottee's holding policyDilution RateTotal number of issued sharesBasis for determining the amount to be paidTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioProcedures under the Corporate Code of ConductMost recent equity financingMajor shareholders after the offeringImpact on Business Performance
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Payment of the full issue price for the issuance of the 7th Series of Stock Acquisition Rights, as resolved at the Board of Directors meeting held on 15 July 2026, has been completed.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.